Navigation Links
Lilly Reports Second-Quarter 2011 Results
Date:7/21/2011

tructuring charges.

2011 Earnings Per Share Expectations:2011
Expectations2010
Results% GrowthEarnings per share (reported)$3.85 to $3.95$4.58(14)% to (16)%In-process research and development charges associated with
Boehringer Ingelheim collaboration (2011) and Acrux
licensing agreement (2010)

.23.03Asset impairments and restructuring charges

.17.13Earnings per share (non-GAAP)$4.25 to $4.35$4.74(8)% to (10)%The company now expects total revenue to grow in the mid-single digits, an increase from the prior guidance of low-single digit growth. The company still anticipates that the impact of U.S. health care reform will lower 2011 revenue by $400 million to $500 million. 2011 revenue guidance assumes the company maintains its patent exclusivity for U.S. Strattera sales, and also assumes rapid and severe erosion of global Zyprexa sales after patent expirations in major markets, including the U.S. starting in October 2011, and the continued severe erosion of U.S. Gemzar sales. The company expects these reductions in revenue to be offset by sales growth of Alimta, Cialis, Cymbalta, Effient, Humalog and animal health products.

The company now anticipates that gross margin as a percent of revenue will decline between 2 and 3 percentage points.

Marketing, selling and administrative expenses are now projected to grow in the high-single digits and still include an estimated $150 million to $200 million in non-tax deductible expense for the mandatory pharmaceutical manufacturers fee associated with U.S. health care reform. Research and development expense growth is now projected to be in the low single digits.

Other income is now expected to be a net expense of between $100 million and $175 million.

The tax rate is still expected to be approximately 21 percent on a non-GAAP basis and approximately 20 percent on a reported basis.

Cash flows are still expected to be sufficient to fund capital expenditures that
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimers Disease Research
2. Lilly and Argonne National Laboratory Announce $2 Million Upgrade to Lillys Beamline Capabilities
3. Lilly Donation to Patient Advocate Foundation Expands Services and Access for Patients With Most Common Form of Lung Cancer
4. Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
5. Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System
6. Lilly Quality Leader Walsh Appointed to Companys Executive Committee
7. Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations
8. Lilly Announces New Investment to Further Boost Its Biotechnology Capabilities
9. Lilly Declares Third-Quarter 2011 Dividend
10. Lilly for Better Healthâ„¢ Launches Enhanced Multi-Channel Patient Education Platform
11. Synthes and Lilly Sign Development and Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
(Date:1/15/2014)... Jan. 15, 2014  In an unprecedented effort to curb the spread ... and other transport vehicles, an advanced and portable UV germicidal lamp ... the first time. In order to prevent EMS ... pathogens, West Palm Beach Fire Rescue is ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... FRANCISCO, Calif., June 01, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, ... from ongoing clinical,studies of SNS-595 and SNS-032 at ... being held June 7-10, 2007 in Vienna,Austria. , ... Phase 1 clinical trial of SNS-595 in acute ...
... Zurich, June 1, 2007-Cytos Biotechnology AG is ... presentations of its novel,immunotherapeutic CYT003-QbG10 to treat ... were obtained,and will be presented in different ... Academy of Allergology and Clinical Immunology,(EAACI), taking ...
Cached Medicine Technology:Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 2Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 3CYT003-QbG10 to treat allergy to be presented at the Congress of,the European Academy of Allergology and Clinical Immunology,(EAACI), June 9-13, 2007 2
(Date:4/23/2014)... Physical Activity on Mobility Limitation in Old Age , ... of mobility limitation in old age, whereas leisure-time physical ... study which followed up 5,200 public sector employees for ... Research Center in Finland and the Finnish Institute of ... wears the body and lasts for several hours a ...
(Date:4/23/2014)... have shown that proliferation of endogenous neural precursor ... neurons and axons. From the perspective of neural ... Yat-sen University in China observed the effects of ... cell proliferation and expression of basic fibroblast growth ... brain on the infarct side. The researchers found ...
(Date:4/22/2014)... Government and industry leaders visited the New Jersey ... President Joel S. Bloom for the launch of ... corporation that provides a new model for business ... higher education assets and investment. U.S. Senator Cory ... CEO Joe Taylor, New Jersey Lieutenant Governor Kim ...
(Date:4/22/2014)... provide primary care for low-income patients may ease ... companies while improving patient health, researchers have concluded. ... health clinics that avoid costs associated with insurance ... hospital admission rates and emergency room visits, according ... Altoona. , The researchers estimated that the ...
(Date:4/22/2014)... of pregnancy among women using a newer method of ... times greater over a 10-year period than using the ... at Yale University and UC Davis has found. ... Contraception , the study found the higher risk of ... brand name Essure. , "This study provides essential ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... April 6 (HealthDay News) -- Compared with normal weight ... and infections during and after a hysterectomy, a new ... 20,353 women who had a hysterectomy to treat non-cancerous ... tumors and pain. Women with a body-mass index ...
... able to predict which adults with mild cognitive impairment are ... results of a study published online and in the June ... is an intermediate stage between the decline in mental abilities ... associated with dementia, a group of brain disorders that includes ...
... national prescribing patterns shows that more than half of ... filled another opioid prescription within the previous 30 days. ... at reducing abuse of prescription opioids. Researchers from ... of the National Institutes of Health, will publish results ...
... , TUESDAY, April 5 (HealthDay News) -- For people ... promise, researchers report. The device, surgically placed just ... jolt to the carotid arteries. This is said to ... activation therapy. The researchers were scheduled to present ...
... persistence and recurrence of H5N1 avian influenza in endemic regions ... birds. Trade in poultry, poultry products and caged birds, and ... these areas. Several recent outbreaks of avian influenza have suggested ... the virus over long distances. In a paper ...
... April 5 (HealthDay News) -- The substantial increase in ... emergency departments between 1995 and 2008 highlights the need ... researchers. They analyzed National Hospital Ambulatory Medical Care ... rose from about 330,000 in 1995 to 1.65 million ...
Cached Medicine News:Health News:Weight Linked to Complications in Some Hysterectomy Patients 2Health News:Using MRI, researchers may predict which adults will develop Alzheimer's 2Health News:Analysis of opioid prescription practices finds areas of concern 2Health News:Implantable Device May Lower Tough-to-Treat Hypertension 2Health News:Implantable Device May Lower Tough-to-Treat Hypertension 3Health News:Migratory birds, domestic poultry and avian influenza 2Health News:Migratory birds, domestic poultry and avian influenza 3Health News:As CT Scans of Kids Soar, Experts Urge Oversight 2
The Accuref 8001 allows you to measure much smaller pupils than conventional units and 3 step Target light adjuster ensures accurate results....
Sterile perfluorocarbon for intraocular Application....
Alcon offers medical grade perfluoropropane (SF6) intraocular gases for ophthalmological use....
Round knurled handle. Overall length 130 mm....
Medicine Products: